Unknown

Dataset Information

0

Aberrant overexpression of an epithelial marker, 14-3-3sigma, in a subset of hematological malignancies.


ABSTRACT: BACKGROUND: 14-3-3sigma is a p53-mediated cell-cycle inhibitor in epithelial cells. The expression of 14-3-3sigma is frequently altered in cancers of epithelial origin associated with altered DNA methylation. Since its involvement in a non-epithelial tumor is unknown, we examined 14-3-3sigma expression in patients with haematological malignancies. METHODS: We analyzed 41 hematopoietic cell lines and 129 patients with a variety of hematological malignancies for 14-3-3sigma expression with real-time RT-PCR. We also examined protein levels by Western blot analysis and DNA methylation status of the 14-3-3sigma gene by methylation-specific PCR analysis of bisulfite-treated DNA. In addition, mutations of p53 gene were identified by RT-PCR-SSCP analysis and the expression levels of 14-3-3sigma were compared with those of other cell-cycle inhibitor genes, CDKN2A and ARF. RESULTS: The expression levels of 14-3-3sigma mRNA in almost all cell lines were low and comparable to those in normal hematopoietic cells except for 2 B-cell lines. On the contrary, 14-3-3sigma mRNA was aberrantly overexpressed frequently in mature lymphoid malignancies (30 of 93, 32.3%) and rarely in acute leukemia (3 of 35, 8.6%). 14-3-3sigma protein was readily detectable and roughly reflected the mRNA level. In contrast to epithelial tumors, methylation status of the 14-3-3sigma gene was not associated with expression in hematological malignancies. Mutations of p53 were identified in 12 patients and associated with lower expression of 14-3-3sigma. The expression levels of 14-3-3sigma, CDKN2A and ARF were not correlated with but rather reciprocal to one another, suggesting that simultaneous overexpression of any two of them is incompatible with tumor growth. CONCLUSION: 14-3-3sigma, an epithelial cell marker, was overexpressed significantly in a subset of mature lymphoid malignancies. This is the first report of aberrant 14-3-3sigma expression in non-epithelial tumors in vivo. Since the significance of 14-3-3sigma overexpression is unknown even in epithelial tumors such as pancreatic cancers, further analysis of regulation and function of the 14-3-3sigma gene in non-epithelial as well as epithelial tumors is warranted.

SUBMITTER: Motokura T 

PROVIDER: S-EPMC2222637 | biostudies-literature | 2007

REPOSITORIES: biostudies-literature

altmetric image

Publications

Aberrant overexpression of an epithelial marker, 14-3-3sigma, in a subset of hematological malignancies.

Motokura Toru T   Nakamura Yukari Y   Sato Hiroyuki H  

BMC cancer 20071125


<h4>Background</h4>14-3-3sigma is a p53-mediated cell-cycle inhibitor in epithelial cells. The expression of 14-3-3sigma is frequently altered in cancers of epithelial origin associated with altered DNA methylation. Since its involvement in a non-epithelial tumor is unknown, we examined 14-3-3sigma expression in patients with haematological malignancies.<h4>Methods</h4>We analyzed 41 hematopoietic cell lines and 129 patients with a variety of hematological malignancies for 14-3-3sigma expression  ...[more]

Similar Datasets

| S-EPMC2828677 | biostudies-literature
| S-EPMC2780041 | biostudies-literature
| S-EPMC3029705 | biostudies-literature
| S-EPMC6709701 | biostudies-literature
| S-EPMC5039560 | biostudies-literature
| S-EPMC7779757 | biostudies-literature
| S-EPMC7704698 | biostudies-literature
| S-EPMC5422942 | biostudies-literature
| S-EPMC3265224 | biostudies-literature
| S-EPMC10137140 | biostudies-literature